Clinical trials: HCC - Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with Tislelizumab and Lenvatinib in patients with advanced-stage hepatocellular carcinoma (HCC).
- Trial name
- CHANCE2602 (NCT07836309)
- Where
- China
- Volunteers
- 596 people
- Sponsor
- Zhongda Hospital
Cancer, Renal Cell Carcinoma (RCC)
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to…
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)
- Trial name
- NCT07620574
- Testing
- Cabozantinib, Zanzalintinib, Atezolizumab
- Where
- 2 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Exelixis
Hepatoblastoma, Hepatocellular Carcinoma (HCC)
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are…
- Conditions
- Hepatoblastoma, Hepatocellular Carcinoma (HCC), Liver Neoplasms, Metastatic Liver Cancer
- Trial name
- ARYA-2 (NCT04634357)
- Testing
- ET140203 T Cells
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Eureka Therapeutics Inc.
Solid Tumors, Hepatocellular Carcinoma (HCC)
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
In this first-in-human, muticenter, non-randomized, open-label, standard 3+3 dose escalation Phase I study encompasses 5 parts (Part 1-5).
- Conditions
- Solid Tumors, Hepatocellular Carcinoma (HCC), Malignant Melanoma, Pediatric Cancer
- Trial name
- NCT06636435
- Testing
- CBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3
- Where
- 5 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Chiome Bioscience Inc.
Huge Hepatocellular Carcinoma (HCC) (>10cm)
The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort Study
This retrospective cohort study collected data of patients with huge hepatocellular carcinoma (HCC) treated between June 1, 2018, and December 31, 2023, through the hospital information system.
- Trial name
- NCT07639294
- Testing
- hepatectomy without immune checkpoint inhibitors-based adjuvant therapy, hepatectomy with immune checkpoint inhibitors-based adjuvant therapy, neoadjuvant conversion therapy followed by surgery
- Where
- China
- Volunteers
- 715 people
- Sponsor
- Tongji Hospital
Advanced Solid Tumors, Ewing Sarcoma
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
- Conditions
- Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC)
- Trial name
- NCT07197554
- Testing
- ST-01156
- Where
- 6 sites in United States
- Volunteers
- 171 people
- Sponsor
- SEED Therapeutics, Inc.
Colorectal Cancer (CRC), Pancreatic Cancer
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
This is an expanded access program (EAP) designed to provide access to Botensilimab and Balstilimab prior to drug registration by the applicable local regulatory agency.
- Conditions
- Colorectal Cancer (CRC), Pancreatic Cancer, Non-Small Cell Lung Cancer (NSCLC), Hepatocellular Carcinoma (HCC)
- Trial name
- NCT06751524
- Testing
- Botensilimab, Balstililmab
- Sponsor
- Agenus Inc.
Hepatocellular Carcinoma (HCC), Second Line Treatment
A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma
The goal of this prospective Phase II clinical trial is to evaluate the efficacy and safety of QL1706-based combination therapy in patients with hepatocellular carcinoma (HCC) who have failed prior targeted-immunotherapy (e.g.…
- Trial name
- DRIVE-II (NCT07138885)
- Testing
- HAI-FOLFOX + bevacizumab + QL1706, TACE + bevacizumab + TAS-102 + QL1706
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-sen University
Melanoma, Hodgkin Lymphoma
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors.
- Conditions
- Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM)
- Trial name
- NCT06521567
- Testing
- Cobolimab, Dostarlimab
- Where
- 20 sites in United States, Czechia and 4 more
- Volunteers
- 83 people
- Sponsor
- GlaxoSmithKline
Hepatocellular Carcinoma (HCC)
Role of Long Noncoding RNA LINC01134 in Metastasis of Hepatitis C Virus-related Hepatocellular Carcinoma
LINC01134, a novel lncRNA, has received increasing attention in cancer research, particularly in hepatocellular carcinoma (HCC).
- Trial name
- NCT07130474
- Volunteers
- 50 people
- Sponsor
- Sohag University
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK
Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma 3 Gene Methylation Combination Detection Kit (PCR Fluorescent Probe Method) Multicenter Clinical Trial
This clinical trial aims to systematically evaluate the clinical performance and accuracy of the HepaAiQ test kit, a multi-gene methylation assay based on PCR with fluorescent probe detection.
- Trial name
- NCT06842563
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Singlera Genomics Inc.
Hepatocellular Carcinoma (HCC)
Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma
This retrospective observational study aims to evaluate whether artificial intelligence (AI) models can predict aggressive recurrence in patients who underwent liver resection for early-stage hepatocellular carcinoma (HCC).
- Trial name
- NCT07030842
- Testing
- liver resection
- Where
- China
- Volunteers
- 579 people
- Sponsor
- Tongji Hospital
HEPATITIS C (HCV), Hepatitis B Virus (HBV)
Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France
In Mongolia, mortality from hepatocellular carcinoma (HCC) is one of the highest in the world. Viral hepatitis is the main cause of HCC: the prevalence of hepatitis B (HBV) estimated at 11% In Mongolia, hepatitis C (HCV) at 8.5%…
- Conditions
- HEPATITIS C (HCV), Hepatitis B Virus (HBV), Hepatitis D, Hepatocellular Carcinoma (HCC)
- Trial name
- Mondelta (NCT07038863)
- Testing
- Community screening for hepatitis B, C and delta in the Mongolian population living in France
- Where
- 11 sites in France
- Volunteers
- 2,000 people
- Sponsor
- Hospices Civils de Lyon
Hepatocellular Carcinoma (HCC)
Triple Recipient Strategy Using Split, Domino, and Auxiliary Techniques
The investigators report a case of the simultaneous use of split liver transplantation (SLT), domino liver transplantation (DLT) and auxiliary liver transplantation (ALT) to achieve "one donor for three recipients".
- Trial name
- NCT06683820
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma (HCC)
Artificially Intelligent Model for Accurate Detection of HCC
Purpose: Integrating comprehensive information on hepatocellular carcinoma (HCC) is essential to improve its early detection. The investigators aimed to develop a model with multi-modal features (MMF) using artificial…
- Trial name
- NCT06637059
- Testing
- observational study
- Where
- China
- Volunteers
- 1,092 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma (HCC), DGF
A Retrospective Cohort Study on Predicting Delayed Graft Function in Liver Transplant Patients with Hepatocellular Carcinoma: a Nomogram and Machine Learning Approaches.
Background: This study aimed to develop a predictive model for delayed graft function (DGF) in liver transplant patients with hepatocellular carcinoma (HCC) based on preoperative biochemical indicators, using both logistic…
- Trial name
- NCT06626724
- Testing
- Liver transplantation
- Where
- China
- Volunteers
- 131 people
- Sponsor
- Jian You
HCC - Hepatocellular Carcinoma
Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma
ABSTRACT Objective: To detect presence of a residual tumor in patients of hepatocellular carcinoma (HCC) treated with Lipiodol based conventional trans arterial chemoembolization (cTACE) using density measurements on follow-up…
- Trial name
- NCT06602986
- Testing
- TACE
- Where
- Pakistan
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Pak Emirates Military Hospital
HCC - Hepatocellular Carcinoma
Comparison of Gd-EOB-DTPA-enhanced MRI and Contrast-enhanced Ultrasound for Measuring Tumor Size of Solitary Hepatocellular Carcinoma ≤ 5cm:A Retrospective Study
Knowing the tumor size before operation is of great significance to the choice of treatment methods of surgeons and the prognosis of patients.
- Trial name
- NCT06437457
- Testing
- ceus
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Anhui Medical University